Findings are from a large-scale cohort study in the Netherlands.
-
-
The combination was well tolerated in a phase 2 cohort study.
-
Findings suggest that outcomes might be improved with targeted physical activity and exercise recommendations.
-
Individualized niraparib dosing is effective and safe.
-
Results are from a meta-analysis of 36 studies.
-
Standalone RECIST or CA125 should not be considered for patient selection for surgery.
-
Further investigation in patients with BRCA-mutated disease is warranted.
-
Findings from a cross-sectional survey and qualitative interviews.
-
Pembrolizumab-bevacizumab-cyclophosphamide were well tolerated.
-
Angiopoietin-2 and Tie-2 expression is increased with distal omental metastasis.
-
Patient should be informed of high risk for recurrence while proposing conservative treatment.
-
All 4 administered regimens elicited a response.
-
Patients with ER+ recurrent low-grade serous ovarian cancer derive most benefit.
-
Study supports treatment individualization based on patient and tumor factors.